Significant progress has been made in the research of Chinese scientists in response to Omi Keron

Jimin Trust Group announced that in response to the impact of the new crown Omicron variant strain on the global new crown epidemic prevention and control, Dr.
Deng Sujun from the Macromolecular Innovation Research Institute of Jimin Trusted R&D Center led the team recently Research on the effectiveness of self-developed antibody JMB2002 on Omi Keron, and combined with the team of Professor Xu Huaqiang and Dr.
Yin Wanchao from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, to analyze the structure of Omi Keron spike protein binding receptor ACE2 and JMB2002 binding Omi Keron The structure and structure of the spike protein (Figure 1 and Figure 2) reveal the biological mechanism of Omi Keron's rapid spread and immune escape from the molecular level, and explain the effectiveness of JMB2002 on Omi Keron from the mechanism.
Corresponding research The results have been published in the preprint version of bioRxiv
.
The latest research results of Jimin Credible show that JMB2002 showed good biological activity and potential anti-virus effect in the Omi Keron pseudovirus neutralization experiment (Figure 2B).
Most of the neutralizing antibodies under research on the market In the case of Omi Keron failure or reduced effect, this result is encouraging
.
One of the reasons for the enhanced transmission power of the Omi Keron mutant is that the receptor binding region of its spike protein and its receptor ACE2 are significantly enhanced compared to wild type.
The development of specific therapeutic antibodies against the Omi Keron mutant is imminent.
Researchers from Jimin Credential found that the binding ability of JMB2002 with the spike protein of Omi Keron mutant strain was 4 times higher than that of the wild-type strain (Figure 2A) The joint team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Jimin Credential successfully The structure of the spike protein of Omi Keron variant strain and the specific therapeutic antibody JMB2002 was analyzed (Figure 2C).
From the obtained structure, the scientists found that the JMB2002 antibody fragment binds to the receptor binding table of RBD in a new conformation.
On the back of the position, there is a new mechanism of action of the antibody (Figure 2D) combined with biochemical and antiviral neutralization experiments.
This joint study explained that the antibody JMB2002 has a broad-spectrum molecular mechanism against the new coronavirus
.
JMB2002 has completed the domestic phase I clinical trial JMB2002 completed the domestic phase I clinical trial in June 2021, and the tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy subjects reached the expected results in 2021 In March, JMB2002 injection was approved by the FDA to carry out clinical trials in the United States
.
At present, Jimin Trust has completed the preparation of 2000 liters of JMB2002 clinical drugs, and the next step of clinical research can be initiated at any time
.